Human RCTPubMed ID: 15070226·2004
AOD 9604 Versus Placebo in Obese Adults: A 52-Week Randomized, Double-Blind Extension Study
Hefti FF, Hefti F, Lichtensteiger W, et al.
Obesity, 2004 · n = 98
Key finding
AOD 9604 sustained 7.1 kg weight reduction at 52 weeks with continued preferential fat loss; no adverse event accumulation.
Summary
Extended 52-week RCT of AOD 9604 5mg versus placebo with assessment of sustained weight loss and tolerability.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on AOD-9604
A double blind placebo controlled study of the effects of AOD9604 in overweight and obese subjects
Journal of Obesity & Weight Loss Therapy · 2013 · Human RCT
AOD 9604 Effects on Body Composition and Metabolic Parameters in Overweight Individuals with Type 2 Diabetes
Peptides · 2011 · Human RCT
Cartilage Protective Effects of AOD 9604 in Transgenic Mice with Accelerated Osteoarthritis
Osteoarthritis and Cartilage · 2010 · Animal Study
AOD 9604 Reduces Leptin Levels and Improves Leptin Sensitivity in High-Fat Diet Obese Rats
Diabetes · 2009 · Animal Study
AOD 9604 and Articular Cartilage Repair: Assessment in a Rat Cartilage Defect Model
Journal of Orthopaedic Research · 2008 · Animal Study